Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management S.J.E. Hwang, R. Anforth, G. Carlos, P. Fernandez-Peñas

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First? D. Moreno-Ramírez, A. Fernández-Orland, L. Ferrándiz

Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review G. Juan-Carpena, J.C. Palazón-Cabanes, M. Blanes-Martínez